Baidu
map

2015 心脏外科手术血液管理专家共识

2015-12-01 中国医师协会心血管外科医师分会 中华胸心血管外科杂志.2015.31(12):715-718.

输血与心脏手术患者近远期不良预后密切相关。采取适宜的血液保护措施,有助于减少心脏手术出血量及用血量。为了规范心血管外科手术围术期血液保护,中国医师协会心血管外科分会及大血管外科专业委员会组织国内心血管外科、麻醉、体外循环、重症监护、血液内科及输血医学专家共同制定了本共识,以期指导临床工作。

中文标题:

2015 心脏外科手术血液管理专家共识

发布日期:

2015-12-01

简要介绍:

输血是外科治疗的一项重要措施。心脏手术难度大、费时长、出血多,用血量在总用血量中占很大比例。美国胸外科医师协会成人心脏手术数据库的资料显示,50%的心脏手术患者接受输血治疗,心脏手术用血量占总用血量的10%~15%1。再次心脏手术、主动脉手术和心室辅助装置置入术用血量更大:输血与心脏手术患者近远期不良预后密切相关。采取适宜的血液保护措施,有助于减少心脏手术出血量及用血量。 

为了规范心血管外科手术围术期血液保护,中国医师协会心血管外科分会及大血管外科专业委员会组织国内心血管外科、麻醉、体外循环、重症监护、血液内科及输血医学专家共同制定了本共识,以期指导临床工作。

 
制定者:
中国医师协会心血管外科医师分会
中国医师协会心血管外科分会大血管外科专业委员会

拓展指南:心脏手术相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2015 心脏外科手术血液管理专家共识)] GetToolGuiderByIdResponse(projectId=1, id=b1f941c0012e708c, title=2015 心脏外科手术血液管理专家共识, enTitle=, guiderFrom=中华胸心血管外科杂志.2015.31(12):715-718., authorId=null, author=, summary=输血与心脏手术患者近远期不良预后密切相关。采取适宜的血液保护措施,有助于减少心脏手术出血量及用血量。为了规范心血管外科手术围术期血液保护,中国医师协会心血管外科分会及大血管外科专业委员会组织国内心血管外科、麻醉、体外循环、重症监护、血液内科及输血医学专家共同制定了本共识,以期指导临床工作。, cover=, journalId=null, articlesId=null, associationId=319, associationName=中国医师协会心血管外科医师分会, associationIntro=null, copyright=0, guiderPublishedTime=Tue Dec 01 00:00:00 CST 2015, originalUrl=, linkOutUrl=, content=<div><p class="MsoNormal">输血是外科治疗的一项重要措施。心脏手术难度大、费时长、出血多,用血量在总用血量中占很大比例。美国胸外科医师协会成人心脏手术数据库的资料显示,50%的心脏手术患者接受输血治疗,心脏手术用血量占总用血量的10%~15%1。再次心脏手术、主动脉手术和心室辅助装置置入术用血量更大:输血与心脏手术患者近远期不良预后密切相关。采取适宜的血液保护措施,有助于减少心脏手术出血量及用血量。<span style="font-size: 9pt;"> </span></p><p class="MsoNormal">为了规范心血管外科手术围术期血液保护,中国医师协会心血管外科分会及大血管外科专业委员会组织国内心血管外科、麻醉、体外循环、重症监护、血液内科及输血医学专家共同制定了本共识,以期指导临床工作。</p>  <br> <span style="font-weight: bold;">制定者:</span><br> 中国医师协会心血管外科医师分会<br> 中国医师协会心血管外科分会大血管外科专业委员会 <div><br> </div> 拓展指南:<strong>与<font color="red">心脏手术</font>相关指南:</strong><br><ul><li><a href="//www.sandwebs.com/guideline/show_article.do?id=b5e541c00115883f" title="我国胸腔镜微创心脏手术技术操作规范专家共识(征求意见稿第二版)" target="_blank">我国胸腔镜微创心脏手术技术操作规范专家共识(征求意见稿第二版)</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=0d5251c0011300a8" title="2014 非心脏手术患者围术期β受体阻滞剂应用中国专家建议" target="_blank">2014 非心脏手术患者围术期β受体阻滞剂应用中国专家建议</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=a2de51c001096026" title="2014 ESC/ESA非心脏手术指南:心血管的评估和管理" target="_blank">2014 ESC/ESA非心脏手术指南:心血管的评估和管理</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=73d451c0010959ff" title="2014 ACC/AHA非心脏手术患者围术期心血管的评估和管理指南" target="_blank">2014 ACC/AHA非心脏手术患者围术期心血管的评估和管理指南</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=f93fd1c00100a4d9" title="2013 ANZSCTS指南:成人心脏手术单元(CSU)的建设" target="_blank">2013 ANZSCTS指南:成人心脏手术单元(CSU)的建设</a></li> 更多信息请点击:<a href="//www.sandwebs.com/guideline/list.do?q=%E5%BF%83%E8%84%8F%E6%89%8B%E6%9C%AF" target="_blank">有关心脏手术更多指南</a></ul></div>, tagList=[TagDto(tagId=23841, tagName=心脏外科手术), TagDto(tagId=19242, tagName=血液管理)], categoryList=[CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6731, appHits=59, showAppHits=0, pcHits=4055, showPcHits=3621, likes=132, shares=0, comments=3, approvalStatus=1, publishedTime=Fri Sep 09 10:50:36 CST 2016, publishedTimeString=2015-12-01, pcVisible=1, appVisible=1, editorId=5295957, editor=lili, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=lili, createdTime=Fri Sep 09 10:50:36 CST 2016, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 14:32:31 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2015 心脏外科手术血液管理专家共识)])
2015 心脏外科手术血液管理专家共识
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1061982, encodeId=d52610619820b, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 17:02:11 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061995, encodeId=05b9106199543, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 17:04:19 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008926, encodeId=17c61008926dc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67634708538, createdName=1356548325, createdTime=Wed Aug 18 09:10:36 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-10-19 湘雅科教

    非常好的文章,受益匪浅。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1061982, encodeId=d52610619820b, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 17:02:11 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061995, encodeId=05b9106199543, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 17:04:19 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008926, encodeId=17c61008926dc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67634708538, createdName=1356548325, createdTime=Wed Aug 18 09:10:36 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-10-19 湘雅科教

    非常好的文章,受益匪浅。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1061982, encodeId=d52610619820b, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 17:02:11 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061995, encodeId=05b9106199543, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 17:04:19 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008926, encodeId=17c61008926dc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67634708538, createdName=1356548325, createdTime=Wed Aug 18 09:10:36 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-18 1356548325

    学习

    0

Baidu
map
Baidu
map
Baidu
map